Immatics N.V. (IMTX)
NASDAQ: IMTX · IEX Real-Time Price · USD
12.52
+0.20 (1.58%)
Jul 19, 2024, 4:00 PM EDT - Market closed
Immatics Employees
Immatics had 535 employees as of December 31, 2023. The number of employees increased by 93 or 21.04% compared to the previous year.
Employees
535
Change (1Y)
93
Growth (1Y)
21.04%
Revenue / Employee
$151,300
Profits / Employee
-$163,147
Market Cap
1.29B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 535 | 93 | 21.04% |
Dec 31, 2022 | 442 | 61 | 16.01% |
Dec 31, 2021 | 381 | 98 | 34.63% |
Dec 31, 2020 | 283 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
Omnicell | 3,650 |
Phreesia | 1,438 |
Establishment Labs Holdings | 908 |
ANI Pharmaceuticals | 642 |
Gyre Therapeutics | 593 |
Arcus Biosciences | 577 |
Sana Biotechnology | 328 |
Ardelyx | 267 |
IMTX News
- 2 months ago - Immatics Announces First Quarter 2024 Financial Results and Business Update - GlobeNewsWire
- 4 months ago - Immatics Announces Full Year 2023 Financial Results and Corporate Update - GlobeNewsWire
- 6 months ago - Immatics Announces Pricing of $175 Million Public Offering - GlobeNewsWire
- 6 months ago - Immatics Announces Proposed Public Offering - GlobeNewsWire
- 8 months ago - Immatics Announces Third Quarter 2023 Financial Results and Business Update - GlobeNewsWire
- 9 months ago - Immatics Reports Interim Clinical Data from ACTengine® IMA203 and IMA203CD8 TCR-T Monotherapies Targeting PRAME in an Ongoing Phase 1 Trial - GlobeNewsWire
- 9 months ago - Immatics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for ACTengine® IMA203 TCR-T Monotherapy - GlobeNewsWire
- 11 months ago - Protalix BioTherapeutics Appoints Eliot Richard Forster, Ph.D. as Chairman of its Board of Directors - PRNewsWire